Neuropeptide Y in neural crest-derived tumors: Effect on growth and vascularization

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 293-302

  Kitlinska, Joanna ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Ewing's sarcoma family of tumors; Neural crest derived tumors; Neuroblastoma; Neuropeptide Y; Pheochromocytoma

Indexed keywords

NEUROPEPTIDE Y;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER MODEL; CELL PROLIFERATION; EWING SARCOMA; HUMAN; NERVOUS SYSTEM TUMOR; NEURAL CREST; NEUROBLASTOMA; NONHUMAN; PARASYMPATHETIC EWING SARCOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, NERVE TISSUE; NEOVASCULARIZATION, PATHOLOGIC; NEURAL CREST; NEUROBLASTOMA; NEUROPEPTIDE Y; SARCOMA, EWING'S;

EID: 33845598968     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.010     Document Type: Article

References (88)

1. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Rose W., Rone J., Movafagh S., Ji H., et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 83 (1998) 187-195
2. Colmers W.F., and Wahlestedt C. The Biology of Neuropeptide and Related Peptides (1993), Humana Press, Totowa, NJ p. xvi, 564
3. Grundemar L.a.B., and Bloom S.R. Neuropeptide Y and Drug Development (1997), Acdemic Press, San Diego
4. Lee E.W., Michalkiewicz M., Kitlinska J., Kalezic I., Switalska H., Yoo P., et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J. Clin. Invest. 111 (2003) 1853-1862
5. Pons J., Kitlinska J., Ji H., Lee E.W., and Zukowska Z. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells:synergetic interactions with the beta-adrenergic system. Can. J. Physiol. Pharmacol. 81 (2003) 177-185
6. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Fisher T.A., and Ji H. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul. Pept. 75-76 (1998) 231-238
7. Hansel D.E., Eipper B.A., and Ronnett G.V. Neuropeptide Y functions as a neuroproliferative factor. Nature 410 (2001) 940-944
8. Grise K.R., Rongione A.J., Laird E.C., and McFadden D.W. Peptide YY inhibits growth of human breast cancer in vitro and in vivo. J. Surg. Res. 82 (1999) 151-155
9. Liu C.D., Slice L.W., Balasubramaniam A., Walsh J.H., Newton T.R., Saxton R.E., et al. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels. Surgery 118 (1995) 229-235 (discussion 235-226)
10. Magni P., and Motta M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann. Oncol. 12 Suppl. 2 (2001) S27-S29
11. Reubi J.C., Gugger M., Waser B., and Schaer J.C. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res. 61 (2001) 4636-4641
12. Yu A., Somasundar P., Balsubramaniam A., Rose A.T., Vona-Davis L., and McFadden D.W. Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor. J. Surg. Res. 105 (2002) 65-68
13. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382 (1996) 168-171
14. Gerald C., Walker M.W., Vaysse P.J., He C., Branchek T.A., and Weinshank R.L. Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J. Biol. Chem. 270 (1995) 26758-26761
15. Larhammar D., Blomqvist A.G., Yee F., Jazin E., Yoo H., and Wahlested C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J. Biol. Chem. 267 (1992) 10935-10938
16. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85 (1999) 9-24
17. Iwata S., and Morimoto C. CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. J. Exp. Med. 190 (1999) 301-306
18. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
19. Ekstrand A.J., Cao R., Bjorndahl M., Nystrom S., Jonsson-Rylander A.C., Hassani H., et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc. Natl Acad. Sci. USA 100 (2003) 6033-6038
20. Ghersi G., Chen W., Lee E.W., and Zukowska Z. Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides 22 (2001) 453-458
21. Koulu M., Movafagh S., Tuohimaa J., Jaakkola U., Kallio J., and Pesonen U. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann. Med. 36 (2004) 232-240
22. Yoon H.Z., Yan Y., Geng Y., and Higgins R.D. Neuropeptide Y expression in a mouse model of oxygen-induced retinopathy. Clin. Exp. Ophthalmol. 30 (2002) 424-429
23. Lee E.W., Grant D.S., Movafagh S., and Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 24 (2003) 99-106
24. Biedler J.L., Roffler-Tarlov S., Schachner M., and Freedman L.S. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38 (1978) 3751-3757
25. Dotsch J., Christiansen H., Hanze J., Lampert F., and Rascher W. Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul. Pept. 75-76 (1998) 185-190
26. Grouzmann E., Comoy E., and Bohuon C. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. J. Clin. Endocrinol. Metab. 68 (1989) 808-813
27. Helman L.J., Cohen P.S., Averbuch S.D., Cooper M.J., Keiser H.R., and Israel M.A. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J. Clin. Oncol. 7 (1989) 1720-1725
28. Kitlinska J., Abe K., Kuo L., Pons J., Yu M., Li L., et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res. 65 (2005) 1719-1728
29. O'Hare M.M., and Schwartz T.W. Expression and precursor processing of neuropeptide Y in human and murine neuroblastoma and pheochromocytoma cell lines. Cancer Res. 49 (1989) 7015-7019
30. Pruszczyk P., Wocial B., Ignatowska-Switalska H., Feltynowski T., Ellafi M., Januszewicz A., et al. Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor?. Clin. Chim. Acta 243 (1995) 205-212
31. Fruhwald M.C., O'Dorisio M.S., Cottingham S.L., Qualman S.J., and O'Dorisio T.M. Neuropeptides in developmental tumors of the central and peripheral nervous system. Ann. NY Acad. Sci. 865 (1998) 420-426
32. Allen J.M., Martin J.B., and Heinrich G. Neuropeptide Y gene expression in PC12 cells and its regulation by nerve growth factor: a model for developmental regulation. Brain Res. 427 (1987) 39-43
33. Magni P., Beretta E., Scaccianoce E., and Motta M. Retinoic acid negatively regulates neuropeptide Y expression in human neuroblastoma cells. Neuropharmacology 39 (2000) 1628-1636
34. Sheriff S., Dayal R., Kasckow J., Regmi A., Chance W., Fischer J., et al. NPY upregulates genes containing cyclic AMP response element in human neuroblastoma cell lines bearing Y1 and Y2 receptors: involvement of CREB. Regul. Pept. 75-76 (1998) 309-318
35. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 (2003) 203-216
36. Maris J.M., and Matthay K.K. Molecular biology of neuroblastoma. J. Clin. Oncol. 17 (1999) 2264-2279
37. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr. 17 (2005) 7-13
38. Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum. Cell 11 (1998) 115-124
39. Schwab M. Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Naturwissenschaften 86 (1999) 71-78
40. Shastry P., Basu A., and Rajadhyaksha M.S. Neuroblastoma cell lines-a versatile in vitro model in neurobiology. Int. J. Neurosci. 108 (2001) 109-126
41. McConville C.M., and Forsyth J. Neuroblastoma-a developmental perspective. Cancer Lett. 197 (2003) 3-9
42. Brodeur G.M., Nakagawara A., Yamashiro D.J., Ikegaki N., Liu X.G., Azar C.G., et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J. Neurooncol. 31 (1997) 49-55
43. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 169 (2001) 107-114
44. Nakagawara A. The NGF story and neuroblastoma. Med. Pediatr. Oncol. 31 (1998) 113-115
45. Nakagawara A., and Brodeur G.M. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur. J. Cancer 33 (1997) 2050-2053
46. Schwab M. MYCN in neuronal tumours. Cancer Lett. 204 (2004) 179-187
47. Westermann F., and Schwab M. Genetic parameters of neuroblastomas. Cancer Lett. 184 (2002) 127-147
48. Cohen P.S., Cooper M.J., Helman L.J., Thiele C.J., Seeger R.C., and Israel M.A. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res. 50 (1990) 6055-6061
49. Kogner P., Bjork O., and Theodorsson E. Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age-adjusted reference interval. Acta Paediatr. 83 (1994) 423-427
50. Minth-Worby C.A. Transcriptional regulation of the human neuropeptide Y gene by nerve growth factor. J. Biol. Chem. 269 (1994) 15460-15468
51. Hofliger M.M., Castejon G.L., Kiess W., and Beck Sickinger A.G. Novel cell line selectively expressing neuropeptide Y-Y2 receptors. J. Recept. Signal Transduct. Res. 23 (2003) 351-360
52. Korner M., Waser B., and Reubi J.C. High expression of neuropeptide y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin. Cancer Res. 10 (2004) 8426-8433
53. Kim H., Li Q., Hempstead B.L., and Madri J.A. Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. J. Biol. Chem. 279 (2004) 33538-33546
54. Barnea A., and Roberts J. Induction of functional and morphological expression of neuropeptide Y (NPY) in cortical cultures by brain-derived neurotrophic factor (BDNF): evidence for a requirement for extracellular-regulated kinase (ERK)-dependent and ERK-independent mechanisms. Brain Res. 919 (2001) 57-69
55. Donovan M.J., Lin M.I., Wiegn P., Ringstedt T., Kraemer R., Hahn R., et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 127 (2000) 4531-4540
56. Eggert A., Ikegaki N., Kwiatkowski J., Zhao H., Brodeur G.M., and Himelstein B.P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 6 (2000) 1900-1908
57. Erdreich-Epstein A., Shimada H., Groshen S., Liu M., Metelitsa L.S., Kim K.S., et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 60 (2000) 712-721
58. Meitar D., Crawford S.E., Rademaker A.W., and Cohn S.L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14 (1996) 405-414
59. Katzenstein H.M., Rademaker A.W., Senger C., Salwen H.R., Nguyen N.N., Thorner P.S., et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin. Cancer Res. 5 (1999) 4273-4278
60. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000) R15-R24
61. Ribatti D., and Ponzoni M. Antiangiogenic strategies in neuroblastoma. Cancer Treat. Rev. 31 (2005) 27-34
62. Ribatti D., Raffaghello L., Marimpietri D., Cosimo E., Montaldo P.G., Nico B., et al. Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett. 197 (2003) 181-184
63. Shusterman S., and Maris J.M. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 228 (2005) 171-179
64. Wassberg E., Hedborg F., Skoldenberg E., Stridsberg M., and Christofferson R. Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am. J. Pathol. 154 (1999) 395-403
65. Papac R.J. Spontaneous regression of cancer: possible mechanisms. In Vivo 12 (1998) 571-578
66. Chlenski A., Liu S., and Cohn S.L. The regulation of angiogenesis in neuroblastoma. Cancer Lett. 197 (2003) 47-52
67. Kogner P., Bjork O., and Theodorsson E. Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med. Pediatr. Oncol. 21 (1993) 317-322
68. Bjellerup P., Theodorsson E., Jornvall H., and Kogner P. Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours. Br. J. Cancer 83 (2000) 171-176
69. Srinivasan B., Roque C.H., Hempstead B.L., Al-Ubaidi M.R., and Roque R.S. Microglia-derived pronerve growth factor promotes photoreceptor cell death via p75 neurotrophin receptor. J. Biol. Chem. 279 (2004) 41839-41845
70. Kovar H. Ewing tumor biology: perspectives for innovative treatment approaches. Adv. Exp. Med. Biol. 532 (2003) 27-37
71. Rodriguez-Galindo C., Spunt S.L., and Pappo A.S. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med. Pediatr. Oncol. 40 (2003) 276-287
72. de Alava E., and Gerald W.L. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J. Clin. Oncol. 18 (2000) 204-213
73. Rorie C.J., Thomas V.D., Chen P., Pierce H.H., O'Bryan J.P., and Weissman B.E. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 64 (2004) 1266-1277
74. Burchill S.A. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J. Clin. Pathol. 56 (2003) 96-102
75. Whang-Peng J., Triche T.J., Knutsen T., Miser J., Kao-Shan S., Tsai S., et al. Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet. Cytogenet. 21 (1986) 185-208
76. Chansky H.A., Hu M., Hickstein D.D., and Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 61 (2001) 3586-3590
77. Lessnick S.L., Braun B.S., Denny C.T., and May W.A. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 10 (1995) 423-431
78. van Valen F., Winkelmann W., and Jurgens H. Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines. J. Cancer Res. Clin. Oncol. 118 (1992) 529-536
79. Langer M., Kratz F., Rothen-Rutishauser B., Wunderli-Allenspach H., and Beck-Sickinger A.G. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem. 44 (2001) 1341-1348
80. Shorter N.A., and Pence J.C. Retinoic acid-induced regulation of neuropeptide Y receptor expression and function in the neuroepithelioma line SK-N-MC. J. Pediatr. Surg. 32 (1997) 721-723
81. Liu J., Kahri A.I., Heikkila P., and Voutilainen R. Regulation of neuropeptide Y mRNA expression in cultured human pheochromocytoma cells. Eur. J. Endocrinol. 141 (1999) 431-435
82. de S.S.P., Denker J., Bravo E.L., and Graham R.M. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J. Clin. Invest. 96 (1995) 2503-2509
83. Chen X., DiMaggio D.A., Han S.P., and Westfall T.C. Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors. Am. J. Physiol. 273 (1997) H1737-H1744
84. Rajakumar P.A., Westfall T.C., and Devaskar S.U. Neuropeptide Y gene expression in immortalized rat hippocampal and pheochromocytoma-12 cell lines. Regul. Pept. 73 (1998) 123-131
85. Mori Y., Higuchi M., Masuyama N., and Gotoh Y. Adenosine A2A receptor facilitates calcium-dependent protein secretion through the activation of protein kinase A and phosphatidylinositol-3 kinase in PC12 cells. Cell Struct. Funct. 29 (2004) 101-110
86. Bournat J.C., and Allen J.M. Regulation of the Y1 neuropeptide Y receptor gene expression in PC12 cells. Brain Res. Mol. Brain Res. 90 (2001) 149-164
87. DiMaggio D.A., Farah Jr. J.M., and Westfall T.C. Effects of differentiation on neuropeptide-Y receptors and responses in rat pheochromocytoma cells. Endocrinology 134 (1994) 719-727
88. Middeke M., Hoffmann S., Hassan I., Wunderlich A., Hofbauer L.C., and Zielke A. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp. Clin. Endocrinol. Diabetes 110 (2002) 386-392